Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

Invest in

Invest in

Invest in

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

 

 

 

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

http://deseret.com/2023/7/18/23798993/fda-approves-new-rsv-drug-beyfortus
Type of Content
Approved Story
1
Format
Hide on the following page types:
Front Page
Tag Pages
Topic Pages
Community Pages
Region Pages
Region
News Item Format
Standard
Community
Story Cluster
Autocurated
1
External ID
526755

The U.S. Food and Drug Administration announced approval of nirsevimab, sold under the name Beyfortus, in a press release Monday. The drug is designed to prevent respiratory syncytial virus lower respiratory tract disease in babies born during or entering their first RSV season, as well as in vulnerable children up to age 2 who are more susceptible to severe illness within their second RSV season. Dr. John Farley, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said in the release, “Today’s approval...